CLINUVEL has a profitable SCENESSE franchise and substantial cash reserves, with an $8.11 base fair value above the $5.58 share price. The assessment remains cautious because nearly all commercial sales depend on one drug, U.S. EPP sales weakened in FY2026, and vitiligo trial results are still uncertain. Stabilization in the U.S. and credible CUV105 data are the key tests for the thesis.
Peer EV/EBITDA observations 6.05x, 6.71x and 19.53x have a 6.71x median. CUVL's FY2026 product revenue fell 1%; the U.S. sales pressure argues against a premium despite higher margin and net cash. The $8.11 base case assumes this U.S. weakness is not a sustained competitive decline. If EBITDA falls to $22M and the multiple contracts to 4x, the modeled bear case is $4.20/share. The EPP multiple already reflects single-product concentration; no generic risk haircut is layered onto it. Risked options total $0.90, 11.1% of base value. Implied core multiple remains 6.71x. Probability-weighted scenario value is $7.97. As a separate EV/revenue cross-check, the 2.60x peer median applied to $65.05M vendor revenue gives ~$169M of enterprise value, or ~$7.68/share after $3.43 net cash and $0.90 risked options; this is about 5% below the $8.11 EBITDA-based base value. $5.58 × 50.43M shares = $281.4M implied capitalization, within 1% of vendor estimates near $283M. Neither cash nor scenario value is guaranteed. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Commercial EPP franchise | $28.44M trailing EBITDA × 6.71x peer-median EV/EBITDA ÷ 50.43M shares | +3.78 |
| Net cash | ($174.37M cash − $1.34M debt) ÷ 50.43M shares | +3.43 |
| CUV105 vitiligo option | 20% success × $151M incremental after-cost NPV ÷ 50.43M shares | +0.60 |
| NEURACTHEL option | 10% success × $100M after-cost NPV ÷ 50.43M shares | +0.20 |
| PhotoCosmetics option | 10% success × $50M after-cost NPV ÷ 50.43M shares | +0.10 |
| Explicit component sum | $3.78 + $3.43 + $0.60 + $0.20 + $0.10 | $8.11 |
USD vendor cash $174.37M less debt $1.34M = net cash $173.03M; company cash reserves were A$252.1M at June 30, 2026. Do not add AUD and USD balances.
Share-price reaction and operating context: CUVL closed at $7.64 on 2026-08-26, $6.16 on 2026-08-28 (-19.4%), and $5.58 on 2026-10-12 (-27.0% versus August 26). The sharp August move followed FY2026 results. Product revenue was A$94.0M versus A$95.0M (-1%); total income including interest was A$101.2M versus A$105.3M (-4%). Management said European growth offset marginally lower U.S. sales, where some competitors offered free EPP treatment and Specialty Centers moved from stocking inventory to just-in-time orders. Global SCENESSE treatment volumes reached a record, so the U.S. sales change does not establish a lasting decline in patient demand. Unrealized FX translation losses on U.S. dollar term deposits were the stated cause of the approximately A$4M pretax-profit decline. The release timing is consistent with a repricing of growth expectations; it cannot identify every trader's motive. Company FY2026 release | CUVL price history.
| Annual, A$M | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total income incl. interest | 83.0 | 95.3 | 105.3 | 101.2 |
| Net profit | 30.6 | 35.6 | 36.2 | 33.9 |
| Cash reserves | 156.8 | 183.9 | 224.1 | 252.1 |
| Operating cash flow (company) | 36.9 | 37.1 | 41.1 | 39.6 |
| Free cash flow (vendor) | 35.88 | 31.48 | 40.8 | 35.31 |
| Metric | H1 FY2025 | H2 FY2025 | H1 FY2026 | H2 FY2026 |
|---|---|---|---|---|
| Product revenue | 35.65 | 59.37 | 36.93 | 57.09 |
| Net profit | 14.08 | 22.10 | 10.44 | 23.47 |
| Cash reserves, period end | 198.22 | 224.11 | 233.00 | 252.06 |
CLINUVEL publishes half-year and annual IFRS results, not a comparable four-quarter income-statement series. H2 revenue and profit above are derived; period-end cash is reported. FY2026 half-year report · FY2025 half-year release.
The FY2026 company press release reports A$36.9M operating cash inflow, while the company's five-year financial summary lists A$39.6M for FY2026. The vendor FY2026 A$35.31M FCF uses A$36.91M operating cash flow less A$1.60M capex. This source discrepancy remains unresolved here; the annual table follows the company's five-year summary and the FCF series follows the vendor. The USD vendor series shows $24.64M FCF. No quarterly IFRS income-statement series is published in the cited annual summary; none is fabricated.
Business model and pipeline
SCENESSE / EPP A$94.0M FY2026 product revenue Approved commercial franchise Afamelanotide implant for erythropoietic protoporphyria. Europe and US treatment infrastructure generates the operating earnings valued in the core EV line. Health Canada granted authorization in July 2026, with launch economics still to be proved. CUV105 / CUV107 vitiligo Phase III program No commercial revenue CUV105 full results are guided to H1 2027 in the annual report. The July SEC exhibit expected preliminary topline in December 2026, compatible with later full results. CUV107 was expected to start in H2 2026. Base option value is risked, not counted as approved sales. NEURACTHEL / PhotoCosmetics Prelaunch options Small risked value Manufacturing progress for NEURACTHEL Instant and planned M-lines launch in H2 2027 remain execution milestones. Together they add $0.30/share risked value in the base model.
Legal, regulatory and risk analysis
A targeted review of recent class-action, short-seller, SEC-investigation and insider-sale references did not verify an additional material proceeding. This is a search outcome, not proof of absence; review ASX and SEC disclosures before reliance.
SWOT analysis
- +FY2026 delivered the tenth consecutive annual profit.
- +Net cash was about $173M, or $3.43 per share, in the USD vendor series.
- +SCENESSE is already commercial in EPP in Europe and the United States.
- +FY2026 operating cash inflow was A$39.6M.
- −Commercial sales remain concentrated in one EPP treatment.
- −FY2026 product revenue fell 1%; U.S. sales faced free-treatment competition and ordering changes.
- −The Nasdaq line has thin daily turnover.
- −R&D spending can consume the apparent cash cushion.
- →Canadian EPP authorization can expand the treated population.
- →CUV105 positive results would open a much larger vitiligo addressable market.
- →CUV107 may refine the Phase III program and regulatory package.
- →NEURACTHEL and PhotoCosmetics create separate, still uncertain options.
- !CUV105 may miss efficacy or safety expectations.
- !Payers or treatment centers could slow geographic expansion.
- !AGM remuneration disputes could distract management.
- !Currency movement between AUD reports and USD shares can distort quick comparisons.
Assessment summary
- Ten years of profit and positive cash flow support the commercial EPP enterprise value.
- FY2026 U.S. sales pressure requires evidence of stabilization.
- Net cash is about 61% of implied equity value.
- Pipeline and launch spending can reduce that cushion.
- Base value of $8.11 is 45.3% above the $5.58 close; the $4.20 bear case is 24.7% below it.
- The range depends on U.S. EPP sales and clinical evidence.
Sources. CLINUVEL FY2026 annual report and official five-year summary : audited financial history, Canada authorization and FY2027 outlook. July 28, 2026 SEC exhibit : preliminary CUV105 topline expected in December 2026, distinct from full results expected in H1 2027. company listing review , AGM date announcement , expired buyback notice and prior remuneration-strike disclosure . CUVL Oct 12 daily close and Yahoo Finance cross-check and 52-week range ; CUVL statistics for shares, cash, debt, FCF and short interest. ASX CUV vendor cash-flow series for AUD free cash flow and FY2026 buybacks. Peer observations: HRMY , BCRX , SUPN . Dated AUD analyst consensus: Sep 15, 2026 compilation . Assumptions for pipeline NPV and scenarios are analyst estimates, not company guidance. Market data — last verified close 2026-10-12: CUVL ~$5.58, market cap ~$281.4M implied, 52W range $5.53–$8.92, 50.43M shares outstanding. Short interest: 12,057 shares, 0.02% of outstanding. Not investment advice.